Mok Q, Underhill G, Wonke B, Aldouri M, Kelsey M, Jefferies D
Whittington Hospital, London.
Arch Dis Child. 1989 Apr;64(4):535-40. doi: 10.1136/adc.64.4.535.
Thirty two patients with beta thalassaemia and sickle cell disease who were having regular blood transfusions were selected to test the efficacy and immunogenicity of low dose (2 micrograms or 0.1 ml) intradermal hepatitis B vaccine compared with the standard (20 micrograms or 1 ml) intramuscular dose. There was no significant difference in the rates of seroconversion, seroconversion had occurred in all patients by seven months. There were no significant differences in antibody titres between the intramuscular and intradermal groups at 1, 2, and 6 months. Although the titres were significantly higher in the intramuscular group at seven months and at 12-18 months, the antibody titre in the intradermal group did not fall below 10 IU/l. The results of this study suggest that low dose intradermal hepatitis B vaccination is an effective and economical way of stimulating an immune response in patients with beta thalassaemia and sickle cell disease.
选取32例接受定期输血的β地中海贫血和镰状细胞病患者，以测试低剂量（2微克或0.1毫升）皮内注射乙肝疫苗与标准（20微克或1毫升）肌肉注射剂量相比的疗效和免疫原性。血清转化率无显著差异，所有患者在7个月时均发生了血清转化。在1、2和6个月时，肌肉注射组和皮内注射组的抗体滴度无显著差异。虽然在7个月以及12 - 18个月时肌肉注射组的滴度显著更高，但皮内注射组的抗体滴度未降至10 IU/l以下。本研究结果表明，低剂量皮内注射乙肝疫苗是刺激β地中海贫血和镰状细胞病患者免疫反应的一种有效且经济的方式。
